Acute Kidney Injury
文献摘要
Acute kidney injury (AKI), previously called acute renal failure, denotes a sudden and often reversible reduction in kidney function, as measured by glomerular filtration rate (GFR) or structural abnormalities. However, immediately after a renal insult, blood urea nitrogen (BUN) or creatinine (Cr) levels may be within the normal range, and the only sign of AKI may be a decline in urine output. AKI can lead to the accumulation of water, sodium, and other metabolic products. AKI can also result in other electrolyte disturbances. AKI is a prevalent condition, especially among hospitalized patients, and can be seen in up to 7% of hospital admissions and 30% of ICU admissions. Several criteria have been used to identify AKI, such as RIFLE, AKIN (Acute Kidney Injury Network), and KDIGO (Kidney Disease: Improving Global Outcomes) criteria. Among these, KDIGO is the most recent and most commonly used tool, using the CKD-EPI criteria to calculate GFR. Although GFR is usually calculated using Cr, equations have now been developed using cystatin C, as measuring this biomarker has become more widespread. CKD-EPI using cystatin C. According to KDIGO, AKI is the presence of any of the following: Increase in serum creatinine by 0.3 mg/dL or more (26.5 μmol/L or more) within 48 hours. Increase in serum creatinine to 1.5 times or more than the baseline of the prior 7 days. Urine volume less than 0.5 mL/kg/h for at least 6 hours. Newer criteria from 2026 propose the addition of the biochemical criteria: Increase in serum cystatin C by ≥1.5 times baseline that is known or presumed to have occurred within the prior 7 days "and the structural criteria". Elevation of a biomarker of kidney damage when used for its clinically validated and regulatory qualified indication, which is known or presumed to have occurred within the prior 7 days" KDIGO AKI criteria 2026. Recommendation 1.1.1: We suggest using serum cystatin C to identify AKI in children and adults in clinical situations when serum creatinine (SCr) is less accurate (2B). Practice Point 1.1.2: A baseline SCr value should be ascertained for all patients with suspected or confirmed AKI. Practice Point 1.1.3: In adults, select the baseline SCr or cystatin C for an AKI episode using a hierarchical approach. The RIFLE criteria define 3 categories of impairment—risk, injury, and failure—and 2 categories of long-term renal outcomes—loss and end-stage renal disease (ESRD). The criterion that shows the greatest impairment is used for classification. When baseline Cr is unknown, a baseline GFR of 75 and 100 mL/min is assumed, or the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation can be used to estimate baseline Cr. Risk: Cr ↑ of 1.5x baseline, GFR ↓ of 25%, or urine output <0.5mL/kg/h for 6 h. Injury: Cr ↑ of 2x baseline, GFR ↓ of 50%, or urine output <0.5mL/kg/h for 12 h. Failure: Cr ↑ of 3x baseline, GFR ↓ of 75 %, Cr ≥4.0, or urine output <0.5mL/kg/h for 12 h. Loss: Loss of kidney function for over 4 weeks. ESRD: Loss of kidney function for over 3 months. The AKIN criteria are based on the RIFLE criteria and are also called the "modified RIFLE" criteria. While the RIFLE and KDIGO systems have higher sensitivity than the AKIN system, all 3 have similar predictive ability for in-hospital mortality.